"
（點擊查看大圖）
[1] 劉鈺琪,張馨月,童南偉.磺脲類藥物的研發和應用歷史[J].藥品評價. 2017,14(03): 12-14+31.
[2] 張徵,鄒大進.糖尿病治療歷史[J].臨床藥物治療雜誌. 2015,13(02): 19-23.
[3] Clifford J. Bailey.Metformin: historical overview[J].Diabetologia.2017,60(9):1566-1576.
[4] White JR Jr.A Brief History of the Development of Diabetes Medications[J].Diabetes Spectr. 2014,27(2): 82-6.
[5] UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J]. Lancet, 1998, 352(9131): 837-853.
[6] Holman RR. Long-term effificacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective[J]. Metabolism, 2006, 55(5 Suppl1): S2-5.
[7] Steven E. Nissen, Kathy Wolski,Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes[J].N Engl J Med 2007;356:2457-2471.
[8] FDA. Guidance for Industry: Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008.
[9] American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesd2020[J]. Diabetes Care 2020;43(Suppl. 1):S98–S110.
[10] Simpson SH, Lee J, Choi S, et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis[J]. Lancet Diabetes Endocrinol 2015;3:43-51.
[11] Rosenstock J, Kahn SE, Johansen OE, et al.Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial[J].JAMA. 2019;322(12):1155-1166.
[12] Aidin Rawshani,Araz Rawshani,Stefan Franzén,et al.Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J],N Engl J Med 2018;379:633-44.
[13] Marso S P , Daniels G H , Brown-Frandsen K , et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[J]. New England Journal of Medicine, 2016:NEJMoa1603827.
[14] 賈偉平,陸菊明.中國2型糖尿病防治指南(2017年版)[J].中華糖尿病雜誌, 2018,10(1): 2-67.
[15] 中華醫學會糖尿病學分會,中華醫學會內分泌學分會.中國成人2型糖尿病患者糖化血紅蛋白控制目標及達標策略專家共識[J].中華內分泌代謝雜誌.2020;36(1):14-24.
閱讀更多 醫脈通內分泌科 的文章
